

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A pharmaceutical, cosmetic, dietetic or nutraceutical composition comprising:

a combination of vasoactive agents consisting of a first vasoactive agent, a second vasoactive agent, and a third vasoactive agent, wherein,

- the first vasoactive agent is visnadin or esculoside,
- the second vasoactive agent is at least one compound selected from the group consisting of icarin, icarin derivatives, extracts containing icarin, ~~Ginkgo~~ Ginkgo *biloba* dimeric flavones either in a free form or complexed with phospholipids, and amentoflavone, and

- the third vasoactive agent is at least one compound selected from the group consisting of escin, escin beta-sitosterol complexed with phospholipids, sericoside, sericoside complexed with phospholipids, and *Centella asiatica* extract in a free form or complexed with phospholipids.

2. (previously presented) The composition as claimed in claim 1, wherein,

the first vasoactive agent is 0.05-2% by weight of the composition,

the second vasoactive agent is 0.1-1% by weight of the composition, and

the third vasoactive agent is 0.5-2% by weight of the composition.

3. (withdrawn) The composition as claimed in claim 1, wherein the icarin derivatives are selected from the group consisting of 7-hydroxyethyl-icarin, 7-ethylamino-icarin, 7-aminoethyl-icarin, 7-hydroxyethyl-3-O-rhamnosyl-icarin, 7-aminoethyl-3-rhamnosyl-icarin, 8-dihydro-icarin and glucosides thereof in 7 and 3, and 7-hydroxyethyl-7-desglucoicarin.

4. (previously presented) The composition as claimed in claim 1, wherein the combination of vasoactive agents is incorporated into a composition is in a form selected from the group consisting of a cream, a gel, a lotion, and a milk.

5. (canceled)

6. (withdrawn) The composition as claimed in claim 1,  
wherein,

the first vasoactive agent is Visnadin,

the second vasoactive agent consists of 7 hydroxyethyl-7  
desgluco-icarin and amentoflavone, and

the third vasoactive agent is escin.

7. (withdrawn) The composition as claimed in claim 1,  
wherein,

the first vasoactive agent is esculoside,

the second vasoactive agent consists of icarin and  
amentoflavone, and

the third vasoactive agent is escin.

8. (withdrawn-currently amended) The composition as  
claimed in claim 1, wherein,

the first vasoactive agent is Visnadin, and

the second vasoactive agent consists of 7 hydroxyethyl-  
7-desgluco-icarin and ~~Ginkgo~~ Ginkgo *biloba* dimers in a free form  
or complexed with phospholipids.

9. (currently amended) The composition as claimed in claim 1, wherein,

the first vasoactive agent is Visnadin,

the second vasoactive agent is ~~Gingke~~ Ginkgo biloba dimers complexed with phospholipids, and

the third vasoactive agent is escin beta-sitosterol complexed with phospholipids.

10. (withdrawn-currently amended) The composition as claimed in claim 1, wherein,

the first vasoactive agent is esculoside,

the second vasoactive agent is ~~Gingke~~ Ginkgo biloba dimers complexed with phospholipids, and

the third vasoactive agent is escin beta-sitosterol complexed with phospholipids.

11-12. (canceled)

13. (currently amended) A pharmaceutical, cosmetic, dietetic or nutraceutical composition comprising:

a combination of vasoactive agents consisting of a

first vasoactive agent, a second vasoactive agent, and a third vasoactive agent, wherein,

- the first vasoactive agent is visnadin,

- the second vasoactive agent is at least one compound selected from the group consisting of icarin, icarin derivatives, extracts containing icarin, ~~Gingko~~ Ginkgo *biloba* dimeric flavones either in a free form or complexed with phospholipids, and amentoflavone, and

- the third vasoactive agent is at least one compound selected from the group consisting of escin, escin beta-sitosterol complexed with phospholipids, sericoside, sericoside complexed with phospholipids, and *Centella asiatica* extract in a free form or complexed with phospholipids.